EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 20 / No 3 (Mars 2004) Med Sci (Paris), 20 3 (2004) 291-297 References
Free Access
Issue
Med Sci (Paris)
Volume 20, Number 3, Mars 2004
Page(s) 291 - 297
Section M/S revues
DOI https://doi.org/10.1051/medsci/2004203291
Published online 15 March 2004
  1. Davies SW, Marchant B, Lyons JP. Irregular coronary lesion morphology after thrombolyis predicts early clinical instability. J Am Coll Cardiol 1991; 18 : 669–74. [Google Scholar]
  2. Theroux P, Fuster V. Acute coronary syndromes. Unstable angina and non-Q-wave myocardial infarction. Circulation 1998; 97 : 1195–206. [Google Scholar]
  3. Braunwald E, Antman EM, Califf RM, et al. ACC/AHA Guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction, 2002. Summary article : a report of the American college of cardiology/American heart association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation 2002; 106 : 1893–900. [Google Scholar]
  4. Verstaete M. A European view on the North American fifth consensus on antithrombotic therapy. Chest 2000; 117 : 1755–70. [Google Scholar]
  5. ISIS-2 collaborative group. Randomized trial of IV streptokinase, oral aspirin, both or neither among 17187 cases of suspected acute myocardial infarction. Lancet 1988; 330 : 1287–94. [Google Scholar]
  6. The clopidogrel in unstable angina to prevent recurrent events trials investigators (CURE). Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345 : 494–502. [Google Scholar]
  7. Steinhubl SR, Berger S, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA 2002; 288 : 2411. [Google Scholar]
  8. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glyco-protein IIb/IIIa inhibitors in acute coronary syndromes : a meta-analysis of all major randomised clinical trials. Lancet 2002; 359 : 189–98. [Google Scholar]
  9. The EPISTENT investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998; 352 : 87–92. [Google Scholar]
  10. The ESPRIT investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT) : a randomised, placebo-controlled trial. Lancet 2000; 356 : 2037–44. [Google Scholar]
  11. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344 : 1895–903. [Google Scholar]
  12. The GUSTO V investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition : the GUSTO V randomised trial. Lancet 2001; 357 : 1905–14. [Google Scholar]
  13. The Assessment of the safety and efficacy of a new thrombolytic regimen (ASSENT)-3 investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab or unfractionated heparin : the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358 : 605–13. [Google Scholar]
  14. Cohen M, Theroux P, Borzak S, et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin : the ACUTE (antithrombotic combination using tirofiban and enoxaparin) II study. Am Heart J 2002; 144 : 470–7. [Google Scholar]
  15. Goodman SG, Fitchett D, Armstrong PW, et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003; 107 : 238–44. [Google Scholar]
  16. Dalby M, Montalescot G, Sollier CB, et al. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. J Am Coll Cardiol 2004; 43 : 162–8. [Google Scholar]
  17. Cannon CP, Weintraub SW, Demopoulos L, et al. A comparison of invasive versus conservative strategy in patients with unstablecoronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344 : 1879–87. [Google Scholar]
  18. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344 : 1888–94. [Google Scholar]
  19. Collet JP, Montalescot G, Fine E, et al. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. J Am Coll Cardiol 2003; 41 : 8–14. [Google Scholar]
  20. Sharma SK, Kini AS, Perez N, et al. Tirofiban, eptifibatide and abciximab in minimizing myocardial damage during high-risk coronary intervention : final results of the TEAM pilot trial. J Am Coll Cardiol 2002; 39 (suppl A) : 73A (abstract 887-5). [Google Scholar]
  21. Gum PA, Kottle-Marchant K, Welch PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41 : 961–5. [Google Scholar]
  22. Collet JP, Himbert D, Steg PG. Myocardial infarction after aspirin cessation in stable coronary artery disease patients. Int J Cardiol 2000; 76 : 257–8. [Google Scholar]
  23. Samama CM, Bastien O, Forestier F, et al. Antiplatelet agents in the perioperative period : expert recommendations of the French society of anesthesiology and intensive care (SFAR) 2001. Summary statement. Can J Anaesth 2002; 49 : S26–35. [Google Scholar]
  24. The EPILOG investigators. Platelets glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularzation. N Engl J Med 1997; 336 : 1689–96. [Google Scholar]
  25. The Epic investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994; 330 : 956–61. [Google Scholar]
  26. The CAPTURE investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina : the CAPTURE study. Lancet 1997; 349 : 1429–35. [Google Scholar]
  27. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and primary PTCA organization and randomized trial (RAPPORT) investigators. Circulation 1998; 98 : 34–41. [Google Scholar]
  28. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346 : 957–66. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.